BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 37624518)

  • 1. Trends in and Prognostic Significance of Time to Treatment in Pancreatic Cancer: A Population-Based Study.
    Sugumar K; Hue JJ; Gupta S; Elshami M; Rothermel LD; Ocuin LM; Ammori JB; Hardacre JM; Winter JM
    Ann Surg Oncol; 2023 Dec; 30(13):8610-8620. PubMed ID: 37624518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased breast cancer mortality due to treatment delay and needle biopsy type: a retrospective analysis of SEER-medicare.
    Pathak R; Leslie M; Dondapati P; Davis R; Tanaka K; Jett E; Chervoneva I; Tanaka T
    Breast Cancer; 2023 Jul; 30(4):627-636. PubMed ID: 37130988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient characteristics and treatment considerations in pancreatic cancer: a population based study in the Netherlands.
    Zijlstra M; van der Geest LGM; van Laarhoven HWM; Lemmens VEPP; van de Poll-Franse LV; Raijmakers NJH
    Acta Oncol; 2018 Sep; 57(9):1185-1191. PubMed ID: 29741436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Adjuvant Hormone Therapy Timing With Overall Survival Among Patients With Hormone Receptor-Positive Human Epidermal Growth Factor Receptor-2-Negative Early Breast Cancer Without Chemotherapy.
    Fu F; Yu L; Zeng B; Chen M; Guo W; Chen L; Lin Y; Hou J; Li J; Li Y; Li S; Chen X; Zhang W; Jin X; Cai W; Zhang K; Chen H; Qiu Y; Nie Q; Wang C; Jacobs L
    JAMA Netw Open; 2022 Feb; 5(2):e2145934. PubMed ID: 35166783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal timing and treatment strategy for pancreatic cancer.
    Gamboa AC; Rupji M; Switchenko JM; Lee RM; Turgeon MK; Meyer BI; Russell MC; Cardona K; Kooby DA; Maithel SK; Shah MM
    J Surg Oncol; 2020 Sep; 122(3):457-468. PubMed ID: 32470166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health Disparities Impact Expected Treatment of Pancreatic Ductal Adenocarcinoma Nationally.
    Lutfi W; Zenati MS; Zureikat AH; Zeh HJ; Hogg ME
    Ann Surg Oncol; 2018 Jul; 25(7):1860-1867. PubMed ID: 29691733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant Radiotherapy is Associated With Improved Pathologic Outcomes and Survival in Resected Stage II-III Pancreatic Adenocarcinoma Treated With Multiagent Neoadjuvant Chemotherapy in the Modern Era.
    Hue JJ; Dorth J; Sugumar K; Hardacre JM; Ammori JB; Rothermel LD; Saltzman J; Mohamed A; Selfridge JE; Bajor D; Winter JM; Ocuin LM
    Am Surg; 2021 Sep; 87(9):1386-1395. PubMed ID: 34382877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends in Preoperative Chemotherapy Utilization for Proximal Pancreatic Cancer: Are We Making Progress?
    Mellado S; Vega EA; Abudalou M; Kutlu OC; Salehi O; Li M; Kozyreva O; Freeman R; Conrad C
    J Gastrointest Surg; 2022 Aug; 26(8):1-7. PubMed ID: 35508681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time intervals to diagnosis and chemotherapy do not influence survival outcome in patients with advanced pancreatic adenocarcinoma.
    Laurent-Badr Q; Barbe C; Brugel M; Hautefeuille V; Volet J; Grelet S; Desot E; Botsen D; Deguelte S; Pitta A; Abdelli N; Brasseur M; De Mestier L; Neuzillet C; Bouché O
    Dig Liver Dis; 2020 Jun; 52(6):658-667. PubMed ID: 32362489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined multiagent chemotherapy and radiotherapy is associated with prolonged overall survival in patients with non-operatively managed stage II-III pancreatic adenocarcinoma.
    Sugumar K; Hue JJ; Hardacre JM; Ammori JB; Rothermel LD; Dorth J; Saltzman J; Mohamed A; Selfridge JE; Bajor D; Winter JM; Ocuin LM
    HPB (Oxford); 2022 Apr; 24(4):433-442. PubMed ID: 34465529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Adjuvant Radiotherapy With Survival After Margin-negative Resection of Pancreatic Ductal Adenocarcinoma: A Propensity-matched National Cancer Database (NCDB) Analysis.
    Kamarajah SK; Sonnenday CJ; Cho CS; Frankel TL; Bednar F; Lawrence TS; Nathan H
    Ann Surg; 2021 Mar; 273(3):587-594. PubMed ID: 30817352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathologic Features and Outcomes of Early-Onset Pancreatic Adenocarcinoma in the United States.
    Ordonez JE; Hester CA; Zhu H; Augustine M; Porembka MR; Wang SC; Yopp AC; Mansour JC; Zeh HJ; Polanco PM
    Ann Surg Oncol; 2020 Jun; 27(6):1997-2006. PubMed ID: 31894482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Insurance and Community-Level Socioeconomic Status With Treatment and Outcome of Squamous Cell Carcinoma of the Pharynx.
    Shin JY; Yoon JK; Shin AK; Blumenfeld P; Mai M; Diaz AZ
    JAMA Otolaryngol Head Neck Surg; 2017 Sep; 143(9):899-907. PubMed ID: 28662244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Treatment Inequity and Ancestry With Pancreatic Ductal Adenocarcinoma Survival.
    Heller DR; Nicolson NG; Ahuja N; Khan S; Kunstman JW
    JAMA Surg; 2020 Feb; 155(2):e195047. PubMed ID: 31800002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Race and Health Disparities in Patient Refusal of Surgery for Early-Stage Pancreatic Cancer: An NCDB Cohort Study.
    Tohme S; Kaltenmeier C; Bou-Samra P; Varley PR; Tsung A
    Ann Surg Oncol; 2018 Nov; 25(12):3427-3435. PubMed ID: 30043318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer.
    Golan T; Sella T; O'Reilly EM; Katz MH; Epelbaum R; Kelsen DP; Borgida A; Maynard H; Kindler H; Friedmen E; Javle M; Gallinger S
    Br J Cancer; 2017 Mar; 116(6):697-702. PubMed ID: 28183138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of immunotherapy on the survival of pancreatic adenocarcinoma patients who received definitive surgery of the pancreatic tumor: a retrospective analysis of the National Cancer Database.
    Amin S; Baine M; Meza J; Alam M; Lin C
    Radiat Oncol; 2020 Jun; 15(1):139. PubMed ID: 32493354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overall survival is increased among stage III pancreatic adenocarcinoma patients receiving neoadjuvant chemotherapy compared to surgery first and adjuvant chemotherapy: An intention to treat analysis of the National Cancer Database.
    Shubert CR; Bergquist JR; Groeschl RT; Habermann EB; Wilson PM; Truty MJ; Smoot RL; Kendrick ML; Nagorney DM; Farnell MB
    Surgery; 2016 Oct; 160(4):1080-1096. PubMed ID: 27522556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CT Abnormalities of the Pancreas Associated With the Subsequent Diagnosis of Clinical Stage I Pancreatic Ductal Adenocarcinoma More Than 1 Year Later: A Case-Control Study.
    Toshima F; Watanabe R; Inoue D; Yoneda N; Yamamoto T; Sasahira N; Sasaki T; Matsuyama M; Minehiro K; Tateishi U; Gabata T
    AJR Am J Roentgenol; 2021 Dec; 217(6):1353-1364. PubMed ID: 34161128
    [No Abstract]   [Full Text] [Related]  

  • 20. Association of health insurance status with presentation, treatment and outcomes in soft tissue sarcoma.
    Jain V; Venigalla S; Sebro RA; Karakousis GC; Wilson RJ; Weber KL; Shabason JE
    Cancer Med; 2019 Oct; 8(14):6295-6304. PubMed ID: 31483578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.